PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx’s Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member ...

PARAMUS, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, held February 2-6, 2026 in San Diego, Calif. These data support the contin ...

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that shares of the Company’s common stock will start trading today on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. “We are pleased to announce that Polaryx’s common stock will begin t ...

PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that shares of the Company’s common stock have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. Shares of Polaryx common stock are expected to commence ...

AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) As filed with the Securities and Exchange Commission on January 27, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Numbe ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Numbe ...

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience in identifying high-quality IPO opportunities [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources including IPO filings, previews, calendars, and a comprehensive guide to IPO investing [1] Group 1 - IPO Edge offers a database of U.S. IPOs and tracks upcoming IPOs, facilitating investors in navigating the IPO lifecycle from filing to listing [1] - The group emphasizes the importance of understanding the quiet period and lockup expiration dates in the IPO process [1]

As filed with the Securities and Exchange Commission on November 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 47-339365 ...